



For Immediate Release

Contact: Meghan Freeman
Meghan.freeman@niconeuro.com
(317) 627.8856

**NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles
Support Access Technology for Deep Brain Lesions**

1,600 completed cases show promising clinical and economic results

WASHINGTON, D.C., May 5, 2015 — Indianapolis-based medical device manufacturer NICO Corporation is seeing market adoption of its innovative line of products including the BrainPath® and Myriad™ technologies offering a complete solution for atraumatically accessing deep-seated brain abnormalities and then removing affected tissue. More than 1,600 procedures have been completed at more than 50 institutions throughout the United States. The technology has also been included in 12 abstracts, three peer-reviewed publications, and seven presentations at national and international neurosurgical conferences.

Over 200 neurosurgeons are trained on technologies that are part of a new integrated surgical approach and more than 100 more are expected to participate in training courses already scheduled this year. The growing clinical evidence demonstrating success of the approach using NICO technologies has been presented at scientific meetings and courses and will be displayed this week at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting.

“We expect to see wider market adoption of our technologies for this underserved patient population, many of whom don’t have a surgical option for their neurological disease state,” says Jim Pearson, president and CEO of NICO Corporation. “With our complete solution to access and tissue removal, we are changing that scenario and giving patients and their loved ones hope where there may have been none before. Our technology, and the physicians who use it, are making important changes in neurosurgery that impact patient outcomes. This matters to the millions who are impacted by diseases of the brain every year.”

The BrainPath technology provides atraumatic access to the brain and is helping redefine the notion of “inoperable” when it comes to brain surgery. BrainPath is used to access and navigate through the delicate folds and fiber tracks of the brain by displacing brain tissue as it creates a corridor to the abnormality, all through an opening the size of a dime. There is no other technology on the market that allows for atraumatic access within the brain using a trans-sulcal surgical approach, which may enable advancements in brain surgery similar to those in knee surgery when the progression was made from open to arthroscopic surgery. Collected clinical data of BrainPath procedures demonstrates the possibility that BrainPath may be used

in functional neurosurgery, trauma and anywhere that non-distributive access is a key challenge to treatment of brain abnormalities in what is a very complex surgical environment.

A multi-center pilot study involving 10 centers featuring BrainPath was recently presented at the International Stroke Conference (ISC). Dr. J.D. Day, professor and chair of the Department of Neurosurgery at the University of Arkansas for Medical Sciences (UAMS), will be discussing his experiences with the approach using BrainPath for the access and removal of brain abnormalities this week at the AANS during a private dinner event.

“We have worked very hard to demonstrate utility of this new surgical approach through compelling clinical evidence,” says Dr. Day. “This approach has added value to my surgical practice by allowing me to offer my patients options that were not possible before.”

You can learn more about the NICO family of products at booth #839 at the AANS or by visiting the website at www.NICOneuro.com. Procedure videos showing atraumatic access with BrainPath can be found on YouTube at NICOneuroCorp.